Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.48 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.42 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.40 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | GRM5 | P41594 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4722336 | 1.00 | MEN1 (0.48) | MEN1KMT2AHRH3P4HTMPDE3B | |
| SCHEMBL7634250 | 0.89 | P4HTM (0.41) | MEN1KMT2AHRH3P4HTMPDE3B | |
| SCHEMBL29142488 | 0.76 | KMT2A (0.50) | MEN1KMT2AHRH3SMN1; SMN2NPC1 | |
| SCHEMBL29142493 | 0.76 | KMT2A (0.50) | MEN1KMT2AHRH3SMN1; SMN2NPC1 | |
| SCHEMBL29142457 | 0.73 | KMT2A (0.49) | MEN1KMT2AHRH3SMN1; SMN2NPC1 | |
| SCHEMBL29142463 | 0.73 | KMT2A (0.49) | MEN1KMT2AHRH3SMN1; SMN2NPC1 | |
| SCHEMBL4769381 | 0.71 | P4HTM (0.42) | MEN1KMT2AP4HTMGRM5ALDH1A1 | |
| SCHEMBL8411263 | 0.69 | HRH3 (0.64) | MEN1KMT2AHRH3NPC1RAB9A | |
| SCHEMBL29142483 | 0.69 | MEN1 (0.54) | MEN1KMT2AHRH3 | |
| SCHEMBL29142478 | 0.69 | MEN1 (0.54) | MEN1KMT2AHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8710062-B2 | Piperazinedione compounds | TAIPEI MEDICAL UNIVERSITY (TW) | 2014-04-29 | — | — | US | disclosed |
| WO-2012125447-A2 | PIPERAZINEDIONE COMPOUNDS | TAIPEI MEDICAL UNIVERSITY (TW) | 2012-09-20 | — | — | WO | disclosed |
| US-20120232088-A1 | PIPERAZINEDIONE COMPOUNDS | NATIONAL TAIWAN UNIVERSITY (TW) | 2012-09-13 | — | — | US | disclosed |
| EP-1282609-B1 | PIPERAZINEDIONE COMPOUNDS | ANGIORX CORP (TW) | 2008-12-17 | — | — | EP | disclosed |
| US-7288545-B2 | Piperazinedione compounds | ANGIORX CORPORATION (TW) | 2007-10-30 | — | — | US | disclosed |
| US-7288545-B2 | Piperazinedione compounds | ANGIORX CORPORATION (TW) | 2007-10-30 | — | — | US | disclosed |
| US-20040132738-A1 | Piperazinedione compounds | ANGIORX CORPORATION (TW) | 2004-07-08 | — | — | US | disclosed |
| US-6635649-B2 | 3-((5-butoxy-pyrid-2-yl)methylene),6-benzylidene-piperazin-2,5 -dione, for example; treating tumors | ANGIORX CORPORATION (TW) | 2003-10-21 | — | — | US | disclosed |
| EP-1282609-A4 | PIPERAZINEDIONE COMPOUNDS | ADPHARMA INC (TW) | 2003-06-04 | — | — | EP | disclosed |
| EP-1282609-A2 | PIPERAZINEDIONE COMPOUNDS | Adpharma Inc. (TW) | 2003-02-12 | — | — | EP | disclosed |
| WO-2001095858-A2 | PIPERAZINEDIONE COMPOUNDS | ADPHARMA, INC. (TW) | 2001-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232088-A1 | PIPERAZINEDIONE COMPOUNDS | ABL1, ERBB2, PAK5 | MEN1 2101/4885KMT2A 544/4885HRH3 3129/4885 |
| US-20040132738-A1 | Piperazinedione compounds | CBR1, KDR, FLT1 | MEN1 4806/4885KMT2A 2913/4885HRH3 549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.